Vigeo Therapeutics Inc is categorized under Commercial Biotechnical Research in Boston, MA and active since 2011.
Vigeo Therapeutics Inc was established in 2011, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Randolph Watnick at the company’s single location by writing to 50 Rowes Wharf, Boston, Massachusetts MA 02110 or by phoning (617) 330-7046. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Vigeo Therapeutics Inc |
| Contact Person: | Randolph Watnick |
| Address: | 50 Rowes Wharf, Boston, Massachusetts 02110 |
| Phone Number: | (617) 330-7046 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Vigeo Therapeutics Inc was started in 2011 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Randolph Watnick for inquiries that concern Vigeo Therapeutics Inc by calling the company number (617) 330-7046, as your correspondence is most welcome. Additionally, the physical location of the single location of Vigeo Therapeutics Inc can be found at the coordinates 42.356593,-71.050595 as well as the street address 50 Rowes Wharf in Boston, Massachusetts 02110.
For its online presence, you may visit Vigeo Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.